ICON plc’s Post

Is the perfect wave of biotech coming our way in 2024? If so, it would bring new and exciting opportunities for VC’s, investors and the entire industry!   Despite the low number of VC investments in Germany in 2023, the life science sector has proven to be resilient.    “We see all the signals that in 2024 significantly more money will flow into biotech,” says Stefan Fischer in his latest column.    TVM Capital Life Science is well positioned to ride the wave: We pursue a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages our strategic relationship with global pharmaceutical firm, Eli Lilly and Company. We also invest in differentiated late clinical-stage therapeutics and commercial-stage medical technologies, as seen with our new portfolio additions myo and Vektor Medical, Inc. 🌟   Dive deeper into what 2024 could hold for the biotech sector by reading the full column on the Plattform Life Sciences website (in German): Die Kunst des Wellenreitens | GoingPublic.de #biotech #medtech #innovation #VentureCapital #investment 

How has Swiss biotech been performing in 2023? 📈 In April the Swiss Biotech Report 2024 was released and its findings were very encouraging for Switzerland's biotech landscape. 2023 marked a 50% increase in capital investment compared to 2022 and reached $2.2 billion. The industry also achieved a revenue of $8 billion in Switzerland. 💸 With public and private companies raising significant funds and Swiss contributions to the cautious yet optimistic IPO market, the country remains a leader in the industry. 🏅 Find out more in the article! ⬇️ https://lnkd.in/devcxekD #swissbiotech #SwissBiotechReport #capitalinvestment #revenuegrowth #IPO #biotechindustry #innovation #healthcare #Switzerland #biotechnews #pharma NewBiologix | Noema Pharma | Alentis Therapeutics | Rejuveron Life Sciences AG | MoonLake Immunotherapeutics (NASDAQ: MLTX) | Lonza | Oculis | CRISPR Therapeutics | Vertex Pharmaceuticals | Novartis | Roche | Flatiron Health | University of Pennsylvania

Positive clinical trial results boost Biopharma valuations, but not to the same degree as negative results lower them, and the degree of impact of valuation is influenced by the therapy area, nature of trial and other factors- this has all been robustly demonstrated in IQVIA’s recent white paper on how clinical trial results impact biopharma valuations - link below. But how can Biopharma use these insights to design trials which maximise positive value impact? Join our webinar which brings the paper’s author William Harries together with #Biopharma CEOs and IQVIA experts to discuss. https://lnkd.in/ezs77Xqe

Fantastic article by HELIO’s Chris Cobourn. If you’re an emerging life sciences company that needs guidance on your launch and Govermment Programs participation, operational requirements and implications - HELIO is here to help!

Join IQVIA for this webinar as their panel of experts provide a thorough understanding of how clinical trial outcomes impact biopharma company valuations. Speakers Catherine Beech MB,ChB,OBE, Amir Hefni, William Harries and Joe Hopcraft will explore the underlying drivers of these impacts, such as trial results compared to investors’ prior expectations, development phase at readout, therapy area, and trial design. https://lnkd.in/gjfAsrua

https://bit.ly/3Y0LSuy Explore how small and midsize biopharma companies are driving innovation, overcoming unique challenges, and maintaining higher clinical success rates than their larger counterparts. Our latest whitepaper, The Golden Era - Unlocking Opportunities for Small and Midsize Biopharma, highlights strategies for navigating complex clinical landscapes and optimizing market access. Download now to discover key insights on overcoming hurdles and turning them into opportunities with the right partnerships. https://bit.ly/3Y0LSuy #Biopharma #Innovation Lujing Wang, Craig Bennison, Zihra Zhuta, Jill Condello, Jessica Smith

Join us for this webinar as our panel of experts provide a thorough understanding of how clinical trial outcomes impact biopharma company valuations. Speakers Catherine Beech MB,ChB,OBE, Amir Hefni, William Harries and Joe Hopcraft will explore the underlying drivers of these impacts, such as trial results compared to investors’ prior expectations, development phase at readout, therapy area, and trial design. https://lnkd.in/gjfAsrua #biotech

In 2023, Massachusetts-based biopharma companies hauled in $7.67 billion in venture capital funding, according to data compiled in the Biopharma Funding and Pipeline Report published today by MassBio. This funding, which was good for 4th all-time and 31% of all national funding, went to 221 companies across 242 rounds. While only two Massachusetts biotechs went public, 38 local companies were acquired to the tune of $13.04 billion. Despite a down year for funding, the local industry has continued to make headlines for getting into the clinic, positive trial results, and FDA approvals, proving their resiliency in the face of headwinds and in taking on some of the most vexing health care challenges. Dive into all the numbers in the full report: https://lnkd.in/evCpuxsC. #biotech #biopharma #venturecapital 

➡️ Takeda's sticky $1.2B partnership ➡️ Two new life science/biotech funds close, totalling $350M+ ➡️ Adderall no longer in short supply ➡️ Two big pharmas ordered to pay Hawaii nearly $1B 🤩 Plus the Fundraises section of the newsletter below All this and more on today's TLDR Biotech - you can find the latest issue on the website (see our LinkedIn page for link). #biotechnews #pharmanews #tldrbiotech

There were some strong moves in the Pharma and Biotech sector in May, with the share prices of 33 companies in the coverage universe rising by 10% or more. In this edition of Mover & Shakers: Pharma & Biotech we take a look at five companies whose share prices rallied during the month.